BRIBF Stock - Brii Biosciences Limited
Unlock GoAI Insights for BRIBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $49.94M | $617,000 | $51.63M | $92.54M | $82.22M |
| Gross Profit | $49.94M | $617,000 | $51.63M | $92.54M | $82.22M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-403,854,000 | $-544,301,000 | $-513,845,000 | $-610,477,000 | $-896,973,000 |
| Net Income | $-508,162,000 | $-174,829,000 | $-484,312,000 | $-4,120,229,000 | $-1,206,287,000 |
| Net Margin | -1017.6% | -28335.3% | -938.1% | -4452.3% | -1467.2% |
| EPS | $-0.70 | $-0.24 | $-0.67 | $-9.48 | $-1.71 |
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Visit WebsiteEarnings History & Surprises
BRIBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q3 2025 | Aug 22, 2025 | $-0.04 | $-0.01 | +62.1% | ✓ BEAT |
Q1 2025 | Mar 21, 2025 | $-0.03 | $-0.04 | -34.8% | ✗ MISS |
Q3 2024 | Aug 19, 2024 | $-0.05 | $-0.05 | -13.1% | ✗ MISS |
Q2 2024 | Jun 25, 2024 | $-0.15 | $0.00 | +102.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.07 | $-0.04 | +46.7% | ✓ BEAT |
Q1 2023 | Mar 24, 2023 | $-0.20 | $-0.03 | +86.2% | ✓ BEAT |
Q3 2022 | Aug 23, 2022 | $-0.73 | $-0.07 | +90.2% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-0.63 | $-0.28 | +55.6% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $0.06 | $-2.30 | -3929.6% | ✗ MISS |
Q2 2021 | Apr 8, 2021 | — | $-0.70 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.23 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.05 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.05 | — | — |
Latest News
Frequently Asked Questions about BRIBF
What is BRIBF's current stock price?
What is the analyst price target for BRIBF?
What sector is Brii Biosciences Limited in?
What is BRIBF's market cap?
Does BRIBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BRIBF for comparison